KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Current Assets (2016 - 2025)

TherapeuticsMD's Current Assets history spans 16 years, with the latest figure at $14.4 million for Q4 2025.

  • For Q4 2025, Current Assets rose 17.83% year-over-year to $14.4 million; the TTM value through Dec 2025 reached $14.4 million, up 17.83%, while the annual FY2025 figure was $14.4 million, 17.83% up from the prior year.
  • Current Assets reached $14.4 million in Q4 2025 per TXMD's latest filing, roughly flat from $14.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $187.0 million in Q1 2021 to a low of $11.5 million in Q1 2024.
  • Average Current Assets over 5 years is $56.4 million, with a median of $18.5 million recorded in 2023.
  • Peak YoY movement for Current Assets: skyrocketed 30.65% in 2021, then plummeted 80.11% in 2023.
  • A 5-year view of Current Assets shows it stood at $119.5 million in 2021, then crashed by 53.67% to $55.4 million in 2022, then crashed by 78.69% to $11.8 million in 2023, then rose by 3.93% to $12.3 million in 2024, then grew by 17.83% to $14.4 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Current Assets are $14.4 million (Q4 2025), $14.5 million (Q3 2025), and $13.5 million (Q2 2025).